Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.

ABSTRACT:

Background and aims

Recent adult evidence suggests that infliximab (IFX) trough levels (TL) in patients with severe ulcerative colitis (UC) may be decreased. The aims of our study were to compare post-induction IFX TL of children with severe versus moderate UC and to evaluate short- and long-term outcomes.

Methods

In this single-center retrospective study, children with a diagnosis of UC starting IFX with a Pediatric Ulcerative Colitis Activity Index (PUCAI) ≥35 and with available post-induction TL were recruited. UC characteristics, IFX dosage and interval, primary non-response, IFX failure, and surgery after 24 months were collected. Post induction TL, anti-IFX antibodies, and laboratory evaluations at the time of starting IFX were also acquired.

Results

A total of

SUBMITTER: Moore H 

PROVIDER: S-EPMC7226697 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature